Home Cart Sign in  
Chemical Structure| 50773-41-6 Chemical Structure| 50773-41-6

Structure of Polyphyllin I
CAS No.: 50773-41-6

Chemical Structure| 50773-41-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Polyphyllin D, a natural product isolated and purified from the rhizomes of Paris yunnanensis Franch. with anti-angiongenic, toxic and anti-cancer effects, induces apoptosis via the mitochondrial apoptotic pathway as evidenced by decreased Bcl-2 expression levels, disruption of MMP and increased Bax, cytochrome C and cleaved-caspase-3 levels.

Synonyms: (+)-Polyphyllin D

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Polyphyllin I

CAS No. :50773-41-6
Formula : C44H70O16
M.W : 855.02
SMILES Code : C[C@@]12[C@@]3([C@]([H])(C[C@]1([C@]4([C@]([H])(CC2)[C@]5(C)C(C[C@H](CC5)O[C@]6([C@H](O[C@]7([C@H](O)[C@H](O)[C@H]([C@@H](O7)C)O)[H])[C@@H](O)[C@@H]([C@H](O6)CO)O[C@@]8(O[C@H]([C@@H]([C@H]8O)O)CO)[H])[H])=CC4)[H])[H])O[C@@]9([C@H]3C)CC[C@H](CO9)C)[H]
Synonyms :
(+)-Polyphyllin D
MDL No. :MFCD12407435

Safety of Polyphyllin I

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Polyphyllin I

MAPK
PI3K-AKT
TLR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Non-small cell lung cancer cells PC9 0.8-1.2 μM 72 h PPI significantly inhibited the growth of PC9 cells and induced cell cycle arrest at G0/G1 phase. PMC4947306
Non-small cell lung cancer cells A549 0.8-1.2 μM 72 h PPI significantly inhibited the growth of A549 cells and induced cell cycle arrest at G0/G1 phase. PMC4947306
PLC 0.1, 0.3, 1 µM 48 h PPI inhibited the transcriptional activity of Twist1 and reduced the expression of VE-cadherin, thereby suppressing VM formation. PMC6125388
SMMC7721 0.1, 0.3, 1 µM 48 h PPI significantly inhibited the migration and invasion ability of HCC cells and reduced the formation of tube-like structures. PMC6125388
L-02 cells 0.66, 0.88, 1.1 mg/mL 24 h To evaluate the cytotoxicity and hepatotoxicity of PPI on L-02 cells, the results showed that PPI dose-dependently decreased cell viability and induced apoptosis and liver dysfunction. PMC9937801
Primary microglia 1 μM and 2 μM 72 h PPI promoted M1 to M2 microglia polarization, reduced the secretion of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and increased the secretion of anti-inflammatory cytokines (IL-4, IL-13, TGF-β). PMC11094947
Peritoneal elucidated macrophages (PEMs) 1 µM 3 h PPI significantly reduced the mRNA expression of IL-1β, IL-6, and iNOS induced by LPS/IFN-γ. PMC6170622
Bone marrow-derived macrophages (BMMs) 0.5 µM, 1 µM 3 h PPI significantly reduced the mRNA expression of IL-1β, TNF-α, IL-6, and iNOS induced by LPS/IFN-γ, and decreased the production of these inflammatory cytokines. PMC6170622
Hep3B 2.1–7 2.5 μg/mL and 5 μg/mL 24 h PPI significantly inhibited the proliferation and migration of Hep3B cells and induced apoptosis PMC11344421
HaCaT keratinocytes 0.3, 0.6, 0.9 μg/ml 8 h PPI significantly reduced TLR2 mRNA and protein expression in a concentration-dependent manner, and downregulated the mRNA and protein expression of IL-1α and K16. PMC6394558
HaCaT keratinocytes 0.3, 0.6, 0.9 μg/ml 24 h PPI significantly suppressed the secretion of inflammatory cytokines, including IL-6, IL-8, and TNF-α, and the expression of TLR2 in P. acnes-treated cells. PMC6394558

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Non-small cell lung cancer xenograft model Intraperitoneal injection 1 mg/kg and 3 mg/kg Once daily for 27 days PPI significantly inhibited tumor growth, reduced protein expression levels of p65, DNMT1 and EZH2, and increased phosphorylation of SAPK/JNK. PMC4947306
BALB/c nude mice HCC xenograft model Oral 10 mg/kg Once daily for 25 days PPI significantly inhibited tumor growth and lung metastasis, and prolonged the survival time of nude mice. PMC6125388
C57BL/6 mice Middle cerebral artery occlusion (MCAO) model Intraperitoneal injection 2 mg/kg and 5 mg/kg Once daily for one week PPI alleviated cerebral ischemia-reperfusion injury and neuroinflammation, improved functional recovery in MCAO mice, and promoted M1 to M2 microglial polarization. PMC11094947
DBA/1J mice Collagen-induced arthritis (CIA) model Intragastric 1 mg/kg Once daily for 7 weeks PPI significantly alleviated arthritis symptoms in CIA mice, reduced joint inflammation and bone erosion, and decreased infiltration of M1-like macrophages. PMC6170622
Zebrafish Hep3B cell xenograft model Culture medium 0.3 μg/mL and 0.6 μg/mL 48 hours PPI significantly inhibited tumor growth of Hep3B cells in the zebrafish model PMC11344421

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.17mL

0.23mL

0.12mL

5.85mL

1.17mL

0.58mL

11.70mL

2.34mL

1.17mL

References

 

Historical Records

Categories